Related Experiment Video
Updated: May 20, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Glucagon like Peptide-1 and atherosclerosis
1Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.
Summary
Glucagon-like peptide-1 based therapies offer type 2 diabetes patients improved glucose control with less hypoglycemia and weight gain. These therapies may also protect against cardiovascular disease by lowering blood pressure and lipids, potentially halting atherosclerosis progression.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) patients face high cardiovascular disease (CVD) risk.
- Traditional T2DM treatments (sulfonylureas, pioglitazone, insulin) can cause hypoglycemia and weight gain, negating glucose-lowering benefits.
- Atherosclerosis is a major complication in T2DM patients.
Purpose of the Study:
- To review the benefits of glucagon-like peptide-1 (GLP-1) based therapies in T2DM management.
- To explore the potential of GLP-1 based therapies in preventing cardiovascular complications.
- To examine the mechanisms by which GLP-1 signaling impacts vascular cells and atherosclerosis.
Main Methods:
- Literature review of recent studies on GLP-1 based therapies in T2DM.
- Analysis of clinical trial data regarding efficacy and safety of GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
- Examination of preclinical data on GLP-1 receptor expression and function in vascular cells.
Main Results:
- GLP-1 based therapies effectively manage hyperglycemia with reduced risk of hypoglycemia and weight gain compared to traditional agents.
- GLP-1 based therapies demonstrate potential cardiovascular benefits, including blood pressure and lipid reduction.
- GLP-1 signaling exhibits anti-inflammatory and vasodilatory effects on endothelial cells, macrophages, and smooth muscle cells, suggesting a role in halting atherosclerosis.
Conclusions:
- GLP-1 based therapies offer a promising alternative for T2DM management, addressing both glycemic control and cardiovascular risk.
- Further large-scale clinical trials are necessary to confirm the atheroprotective effects of GLP-1 based therapies.
- GLP-1 based therapies may provide dual benefits of glucose lowering and cardiovascular protection in T2DM patients.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...